Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: STRO

Sutro Biopharma, Inc.

Healthcare | Biotechnology

No licensed closing price on file for STRO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Sutro Biopharma, Inc. (NASDAQ: STRO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:48 UTC.

What Sutro Biopharma, Inc. does

Stro­thera is a clinical-stage oncology company developing antibody drug conjugates, or ADCs, using its proprietary XpressCF and XpressCF+ platforms for cell-free protein synthesis and site-specific conjugation. The company's lead candidate, STRO-004, is a single homogeneous ADC targeting tissue factor for solid tumors, which entered Phase 1 clinical trials in November 2025.

Summarized from Sutro Biopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity144.27%

Revenue, margins & earnings

FY2021: net loss $106M on revenue $62M$62MFY2021FY2022: net loss $119M on revenue $68M$68MFY2022FY2023: net loss $107M on revenue $154M$154MFY2023FY2024: net loss $227M on revenue $62M$62MFY2024FY2025: net loss $191M on revenue $102M$102MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-22
  • 2026-09-22CHIEF SCIENTIFIC OFFICEROption exercise3,750—
  • 2026-09-22CHIEF SCIENTIFIC OFFICERRestricted Stock Units (RSUs)Option exercise-3,750—
  • 2026-09-22CHIEF SCIENTIFIC OFFICERTax withholding-1,345$20.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Sutro Biopharma, Inc. do?

Stro­thera is a clinical-stage oncology company developing antibody drug conjugates, or ADCs, using its proprietary XpressCF and XpressCF+ platforms for cell-free protein synthesis and site-specific conjugation.

When did STRO last file with the SEC?

Sutro Biopharma, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-08. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:48 UTC. This page is also available as JSON at /api/data?ticker=STRO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for STRO and 5,000+ tickers.

Create a free account — keep STRO
For your agent
GET /api/data?ticker=STRO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt